Self-Shielding Gyroscopic Radiosurgery – A Prospective Analysis and Comparison.

Self-Shielding Gyroscopic Radiosurgery – A Prospective Analysis and Comparison. - GRAY

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00025819

Enrollment

350

Registered

2021-07-16

Start date

2022-10-03

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C79.3 D32 D35.2 Q28.2 Q28.3 D33.3 D33.2 D44.7 C69.3 C69.4 C71 D43 G50.0 D33 E22.0 E22.1

Interventions

Group 1: The radiotherapy for one of the included diseases will be done utilizing gyroscopic radiosurgery (ZAP-X). The prescribed dose, number of fractions, and prescribed isodose line will follow the

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Legal age and radiographic (tumors) or histopathological (tumors) or clinical diagnosis (trigeminal neuralgia) of the listed diseases according to the ICD-10.

Exclusion criteria

Exclusion criteria: Nonage according to the definition of the Federal Republic of Germany

Design outcomes

Primary

Measure	Time frame
For tumors: local tumor control (according to the RECIST 1.1) at last follow-up For trigeminal neuralgia: Visual Analogue Scale (VAS) for pain throughout the available follow-up	—

Secondary

Measure	Time frame
Progression-free survival, overall survival, toxicity according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0) after treatment, quality of life at every follow-up (SF-12, according to the respective tumor: EORTC QLQ-BN20/QLQ-HN35 and QLQ-C30)	—

Countries

Germany

Contacts

Public ContactAlexander Muacevic

Europäisches Cyberknife Zentrum München-Großhadern

info@cyber-knife.net089 4523360

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026